Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Therapeutics Corp.

www.unither.com

Latest From United Therapeutics Corp.

Actelion Is Third Company To Settle Charity Co-Pay Kickback Claims With DOJ

Company agrees to pay $360m to resolve allegations it used a charity as a conduit to pay Medicare patient copays for its drugs; several other companies are under investigation.

Policy Enforcement

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

Market Intel: Cornea, Bio-Drugs, Artificial Hips On Track For 3D Printing

Although certainly not a given, many researchers and companies are pursing the eventual goal of bioprinting human organs, starting with the three-dimensional printing of a structure that has cellular function. If organ function via bioprinting becomes a reality for the skin, bone, lung, liver, eye and/or kidney, among other potential organs, the market opportunity could be in the billions. But challenges, including cost and ethics, stand in the way of this milestone in regenerative medicine.

Regenerative Medicine Market Intelligence

Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate

With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.

Deals Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • United Therapeutics Corp.
  • Senior Management
  • Roger Jeffs, PhD, Pres. & Co-CEO
    James C Edgemond, CFO
  • Contact Info
  • United Therapeutics Corp.
    Phone: (301) 608-9292
    1040 Spring St.
    Silver Spring, MD 20910
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register